Kestra Medical Technologies Ltd. (KMTS)
NASDAQ:KMTS
Top Page
Kestra Medical Technologies Ltd.
(NASDAQ:KMTS)
Select Model
Select Model
Rating:52Neutral
Price Target:
$19.50
▲(2.52% Upside)
Action:ReiteratedDate:12/12/25
Kestra Medical Technologies Ltd. shows promising revenue growth and clinical validation, which are significant strengths. However, ongoing profitability challenges and bearish technical indicators weigh on the overall score. The recent capital raise and positive study results provide some optimism for future growth.
Positive Factors
Revenue & Prescription Growth
Sustained 50%+ revenue and prescription growth reflects accelerating commercial adoption and expanding account activation. Over multiple quarters this indicates improving unit economics and scalable demand that can support durable top-line expansion as the sales organization scales.
Negative Factors
Large Net Losses
Significant and growing GAAP losses create persistent profit headwinds and indicate that current revenue and margin improvements have not yet offset operating costs. Continued sizable losses can pressure liquidity and require meaningful scale or cost reductions to reach sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & Prescription Growth
Sustained 50%+ revenue and prescription growth reflects accelerating commercial adoption and expanding account activation. Over multiple quarters this indicates improving unit economics and scalable demand that can support durable top-line expansion as the sales organization scales.
Read all positive factors
Kestra Medical Technologies Ltd. (KMTS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.14B
Dividend YieldN/A
Average Volume (3M)310.69K
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue Growth62.06%
EPS Growth-41.97%
CountryUS
Employees300
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)N/A
Shares Outstanding58,373,352
10 Day Avg. Volume502,173
30 Day Avg. Volume310,694
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)-5.17
Price to Sales (P/S)38.89
P/FCF Ratio-12.76
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue10.14
Enterprise Value/Gross Profit20.80
Enterprise Value/Ebitda-6.41
Forecast
1Y Price Target
$28.80Price Target Upside51.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kestra Medical Technologies Ltd. Business Overview & Revenue Model
Company Description
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intui...
How the Company Makes Money
null...
Kestra Medical Technologies Ltd. Key Performance Indicators (KPIs)
Kestra Medical Technologies Ltd. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2021 | Apr 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 83.72M | 59.81M | 27.81M | 7.63M | 0.00 | 0.00 |
| Gross Profit | 40.81M | 24.21M | 362.00K | -10.65M | 0.00 | 0.00 |
| EBITDA | -132.51M | -97.98M | -76.31M | -73.74M | -32.33M | -28.84M |
| Net Income | -144.83M | -113.81M | -94.12M | -84.24M | -34.10M | -29.47M |
Balance Sheet | ||||||
| Total Assets | 379.34M | 295.74M | 45.95M | 38.66M | 30.52M | 7.87M |
| Cash, Cash Equivalents and Short-Term Investments | 291.32M | 237.59M | 8.25M | 14.81M | 24.34M | 5.76M |
| Total Debt | 4.29M | 44.31M | 45.17M | 39.13M | 22.85M | 452.00K |
| Total Liabilities | 91.35M | 90.34M | 255.33M | 156.23M | 28.76M | 4.02M |
| Stockholders Equity | 287.99M | 205.41M | -209.38M | -117.58M | 1.77M | 3.86M |
Cash Flow | ||||||
| Free Cash Flow | -119.95M | -101.20M | -84.75M | -85.10M | -30.23M | -30.52M |
| Operating Cash Flow | -86.68M | -77.61M | -72.23M | -69.64M | -29.89M | -30.29M |
| Investing Cash Flow | -38.33M | -23.31M | -12.23M | -15.46M | -334.00K | -232.00K |
| Financing Cash Flow | 361.98M | 330.26M | 77.72M | 96.11M | 48.81M | 30.24M |
Kestra Medical Technologies Ltd. Risk Analysis
Kestra Medical Technologies Ltd. disclosed 75 risk factors in its most recent earnings report. Kestra Medical Technologies Ltd. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Kestra Medical Technologies Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $897.90M | -95.19 | -3.40% | ― | -18.82% | 92.56% | |
52 Neutral | $1.14B | -9.54 | -68.83% | ― | 62.06% | -41.97% | |
52 Neutral | $1.40B | -12.71 | -73.46% | ― | ― | -40.63% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $449.27M | -21.14 | -15.31% | ― | 2.73% | 87.03% | |
51 Neutral | $207.38M | -2.59 | -18.58% | ― | -43.95% | -620.21% | |
46 Neutral | $885.78M | -14.54 | -23.24% | ― | -32.42% | -540.37% |
* Healthcare Sector Average
KMTS
Kestra Medical Technologies Ltd.
19.46
-3.97
-16.94%
ANGO
AngioDynamics
10.90
1.40
14.74%
OSUR
Orasure Technologies
3.00
-0.43
-12.54%
STAA
Staar Surgical
17.89
0.10
0.56%
BLFS
BioLife Solutions
18.59
-7.37
-28.39%
PLSE
Pulse Biosciences
20.57
3.97
23.92%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.